{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:47:15Z","timestamp":1761677235928,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The extensive clinical variations observed in Parkinson's disease (PD) pose challenges in early diagnosis and treatment initiation. However, genetic research in PD has significantly transformed the clinical approach to its treatment. Moreover, researchers have adopted a subtyping strategy based on homogeneous clinical symptoms to improve clinical diagnosis and treatment approaches. We conducted a study to explore clinical characteristics in genetic PD groups with motor symptom subtyping.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data was driven from the Parkinson's Progression Markers Initiative (PPMI) database. The sporadic PD (sPD) group and the genetic PD group including patients with leucine-rich kinase 2 (<jats:italic>LRRK2<\/jats:italic>) or glucosylceramidase \u03b2 (<jats:italic>GBA<\/jats:italic>) mutations were analyzed. Motor subtyping was performed using Movement Disorder Society-Unified Parkinson's disease rating scale (MDS-UPDRS) scores. I-123 FP-CIT SPECT scans were used to calculate specific binding ratios (SBRs) in the caudate and putamen. Clinical symptoms of each group were also compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MDS-UPDRS III scores were lower in the <jats:italic>LRRK2<\/jats:italic> group, compared with the <jats:italic>GBA<\/jats:italic> and sPD group (<jats:italic>P<\/jats:italic> &amp;lt; 0.001), but no significant differences in striatal SBRs. The putaminal SBR value of the <jats:italic>LRRK2<\/jats:italic> group was higher than the sPD group (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). Within the <jats:italic>GBA<\/jats:italic> group, we observed lower SBR values in the postural instability\/gait difficulty (PIGD) subtype <jats:italic>GBA<\/jats:italic> group compared to the tremor-dominant (TD) subtype <jats:italic>GBA<\/jats:italic> group (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). The TD subtype <jats:italic>GBA<\/jats:italic> group exhibited superior putaminal SBRs compared to the TD subtype sPD group (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). The TD subtype <jats:italic>LRRK2<\/jats:italic> group had better putaminal SBR values (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) and MDS-UPDRS Part III scores (<jats:italic>P<\/jats:italic> &amp;lt; 0.05) compared to the TD sPD group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussions<\/jats:title><jats:p>Our subtyping approach offers valuable insights into the clinical characteristics and progression of different genetic PD subtypes. To further validate and expand these findings, future research with larger groups and long-term follow-up data is needed. The subtyping strategy based on motor symptoms holds promise in enhancing the diagnosis and treatment of genetic PD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1276251","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T06:06:30Z","timestamp":1698300390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort"],"prefix":"10.3389","volume":"14","author":[{"given":"Eun Hye","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Ku","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo Sung","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A review of Parkinson's disease","volume":"86","author":"Davie","year":"2008","journal-title":"Br Med Bull."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1002\/mds.21676","article-title":"Update on the genetics of Parkinson's disease","volume":"22","author":"Gasser","year":"2007","journal-title":"Mov Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S1353-8020(13)70009-9","article-title":"Genetics of Parkinson's disease\u2013state of the art, 2013","volume":"20","author":"Bonifati","year":"2014","journal-title":"Parkinsonism Relat Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of Parkinson's syndrome in type I Gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM."},{"key":"B5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in textitLRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron."},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"textitGBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2017.4019","article-title":"Progression in the textitLRRK2-asssociated Parkinson disease population","volume":"75","author":"Saunders-Pullman","year":"2018","journal-title":"JAMA Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","article-title":"How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale","volume":"28","author":"Stebbins","year":"2013","journal-title":"Mov Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1212\/WNL.61.7.931","article-title":"Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD","volume":"61","author":"Louis","year":"2003","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/mds.20897","article-title":"Changes in motor subtype and risk for incident dementia in Parkinson's disease","volume":"21","author":"Alves","year":"2006","journal-title":"Mov Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3389\/fneur.2019.00471","article-title":"Alteration of tremor dominant and postural instability gait difficulty subtypes during the progression of Parkinson's disease: analysis of the PPMI cohort","volume":"10","author":"Lee","year":"2019","journal-title":"Front Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/mds.27989","article-title":"Clinical and dopamine transporter imaging characteristics of leucine rich repeat kinase 2 (textitLRRK2) and glucosylceramidase beta (textitGBA) Parkinson's disease participants in the Parkinson's progression markers initiative: a cross-sectional study","volume":"35","author":"Simuni","year":"2020","journal-title":"Mov Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"976101","DOI":"10.3389\/fneur.2022.976101","article-title":"Serial changes of I-123 FP-CIT SPECT binding asymmetry in Parkinson's disease: analysis of the PPMI data","volume":"13","author":"Jeong","year":"2022","journal-title":"Front Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/ana.24261","article-title":"Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference","volume":"76","author":"Sieber","year":"2014","journal-title":"Ann Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of textitGBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0022-510X(95)00316-T","article-title":"Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms","volume":"136","author":"Otsuka","year":"1996","journal-title":"J Neurol Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S1474-4422(09)70293-5","article-title":"Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms","volume":"8","author":"Rodriguez-Oroz","year":"2009","journal-title":"Lancet Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-7091-6360-3_1","article-title":"Post mortem studies in Parkinson's disease\u2013is it possible to detect brain areas for specific symptoms?","volume":"56","author":"Jellinger","year":"1999","journal-title":"J Neural Transm Suppl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of textitLRRK2-associated Parkinson's disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/1073858417748875","article-title":"Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications","volume":"24","author":"Balestrino","year":"2018","journal-title":"Neuroscientist."},{"key":"B21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-020-0893-5","article-title":"The effect of textitLRRK2 loss-of-function variants in humans","volume":"26","author":"Whiffin","year":"2020","journal-title":"Nat Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/hmg\/ddl471","article-title":"Parkinson's disease-associated mutations in textitLRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity","volume":"16","author":"West","year":"2007","journal-title":"Hum Mol Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1016\/j.neurobiolaging.2015.08.027","article-title":"Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease","volume":"36","author":"Oeda","year":"2015","journal-title":"Neurobiol Aging."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1276251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T06:06:32Z","timestamp":1698300392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1276251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":23,"alternative-id":["10.3389\/fneur.2023.1276251"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1276251","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"article-number":"1276251"}}